Bristol-Myers Squibb Rating Increased to Hold at Jefferson Research (BMY)
Bristol-Myers Squibb (NYSE:BMY) was upgraded by investment analysts at Jefferson Research from a “sell” rating to a “hold” rating in a note issued to investors on Tuesday, Analyst Ratings News reports.
Bristol-Myers Squibb (NYSE:BMY) traded up 1.88% during mid-day trading on Tuesday, hitting $53.00. The stock had a trading volume of 5,798,688 shares. Bristol-Myers Squibb has a one year low of $30.64 and a one year high of $49.57. The stock’s 50-day moving average is $42.73 and its 200-day moving average is $42.60. The company has a market cap of $87.267 billion and a price-to-earnings ratio of 31.22. Bristol-Myers Squibb also saw some unusual options trading activity on Monday. Traders acquired 22,460 call options on the stock. This represents an increase of approximately 145% compared to the typical volume of 9,180 call options.
Bristol-Myers Squibb (NYSE:BMY) last released its earnings data on Wednesday, October 23rd. The company reported $0.46 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.44 by $0.02. The company had revenue of $4.07 billion for the quarter, compared to the consensus estimate of $4.02 billion. During the same quarter in the prior year, the company posted $0.41 earnings per share. The company’s quarterly revenue was up 8.8% on a year-over-year basis. On average, analysts predict that Bristol-Myers Squibb will post $1.74 earnings per share for the current fiscal year.
The company also recently announced a quarterly dividend, which is scheduled for Friday, November 1st. Stockholders of record on Friday, October 4th will be paid a dividend of $0.35 per share. This represents a $1.40 annualized dividend and a dividend yield of 2.69%. The ex-dividend date is Wednesday, October 2nd.
Several other analysts have also recently commented on the stock. Analysts at Credit Suisse reiterated a “focus list” rating on shares of Bristol-Myers Squibb in a research note to investors on Monday. They now have a $55.00 price target on the stock. Separately, analysts at Morgan Stanley upgraded shares of Bristol-Myers Squibb from an “equal weight” rating to an “overweight” rating in a research note to investors on Monday. They now have a $60.00 price target on the stock, up previously from $45.00. Finally, analysts at TheStreet reiterated a “buy” rating on shares of Bristol-Myers Squibb in a research note to investors on Sunday. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating, eleven have issued a buy rating and two have given a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus target price of $49.83.
Bristol-Myers Squibb Company (NYSE:BMY) is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products on a global basis.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.